AZ’s STORM CHASER Falls Short On Ambitious COVID Symptom Goal
But Data Point To Success
Executive Summary
AstraZeneca had wanted to outperform Regeneron and Lilly in post-exposure prevention, but will now hope for more durable protection from its long-acting antibody.
You may also be interested in...
Roche, Lilly Antibody Cocktails Threatened By Delta Plus Variant But More Evidence Needed
Roche and Eli Lilly’s monoclonal antibody cocktails seem to show reduced efficacy against the Delta Plus variant, first identified in Europe, but more evidence might be needed to support the finding. Meanwhile, GSK’s Indian unit is gearing up to submit an application for accelerated approval of sotrovimab.
Regeneron’s Antibody Therapy A Lifesaver In Seronegative COVID-19 Patients
Identifying patients who have not mounted an immune response to SARS-CoV2 and treating them with the antibody cocktail cuts risk of death by a fifth.
GSK/Vir’s Covid Antibody Gains EU Clearance, But Demand May Have Peaked
The green light for the COVID-19 antibody therapy is welcome news for the partners, but rising vaccination rates plus three other competitors in Europe will limit revenues.